A 30 per cent trade margin cap brings reductions across more than 1,000 formulations, with the steepest reported cut at 96.45 per cent. Revised prices for 137 anti-cancer drugs take effect on 9 November, with estimated annual consumer savings of Rs 3,502.31 crore.Price reductions have been reported for 1,031 formulations, including cuts exceeding 50 per cent across 600 brands.Retailers and hospitals must display revised prices, while state drug controllers will monitor compliance.